EFFICACY OF DEUCRAVACITINIB, A FIRST-IN- CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS: A SUBANALYSIS OF THE PHASE 2 PAISLEY STUDY

被引：0

作者：

Pike, M. ^{[1
]}

Saxena, A. ^{[2
]}

Furie, R. A. ^{[3
]}

Nash, P. ^{[4
]}

Doerner, T. ^{[5
]}

Hobar, C. ^{[6
]}

Pomponi, S. ^{[6
]}

Koti, R. ^{[6
]}

Banerjee, S. ^{[6
]}

Wegman, T. ^{[6
]}

Merrill, J. ^{[7
]}

机构：

[1] MedPharm Consulting Inc, Rheumatol, Raleigh, NC 27615 USA

[2] NYU, Dept Med, Grossman Sch Med, Grossman Sch Med, New York, NY USA

[3] Northwell Hlth, Rheumatol, New York, NY USA

[4] Univ Queensland, Dept Med, Brisbane, Australia

[5] Charite, Berlin, Germany

[6] Bristol Myers Squibb, Princeton, NJ USA

[7] Oklahoma Med Res Fdn, Oklahoma City, OK USA

来源：

关键词：

Randomized controlled trial; Bone; Clinical Trial; Outcome measures;

D O I：

10.1136/annrheumdis-2024-eular.1522

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0542

引用

页数：2